Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,409 across all filing types
Latest filing 2021-06-22 Earnings Release
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma présente des données préliminaires de l'essai TELLOMAK montrant une réponse clinique avec lacutamab dans le mycosis fungoides
Earnings Release Classification · 99% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces preliminary clinical trial data (TELLOMAK trial results for lacutamab) presented at a medical conference (16-ICML). It also mentions an upcoming investor event. This format—a formal announcement of recent operational/clinical news intended for broad distribution, rather than a comprehensive periodic financial report (like 10-K or IR) or a transcript—strongly suggests an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on clinical data and operational updates rather than just summarizing quarterly financial performance highlights, it fits best as a general announcement. Given the options, and since it is a press release announcing significant operational/clinical progress, it is classified as an Earnings Release (ER) if it were tied to a reporting period, or RNS if it's purely operational/clinical news. However, press releases announcing clinical data and upcoming investor events often fall under the umbrella of ER when they are the primary means of disseminating material, non-financial news to the market, or RNS as a general regulatory announcement. Since the content is highly specific clinical data and not a summary of financial results, RNS (Regulatory Filings / General Announcement) is the most appropriate fallback for material, non-standard financial disclosures, although ER is often used for clinical updates preceding investor calls. Given the context of a press release detailing clinical trial progress and mentioning an investor event, ER is often the intended category for such market-moving news, but RNS is the safest general regulatory announcement category. I will lean towards ER as it is a major announcement intended to inform the market about recent developments, often preceding or accompanying an earnings/investor call mentioned later in the text. FY 2021
2021-06-22 French
Innate Pharma presents preliminary data from TELLOMAK trial showing clinical response for lacutamab in mycosis fungoides
Earnings Release Classification · 95% confidence The document is a press release dated June 22, 2021, announcing preliminary clinical data from the TELLOMAK trial for the drug lacutamab in Mycosis Fungoides. It details safety, clinical responses, and mentions an upcoming investor event. This format—a formal announcement of recent operational/clinical results, often released before or alongside a more comprehensive report—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational news. Since it focuses on clinical trial results and operational updates rather than comprehensive financial statements (like a 10-K or IR), and it is not a transcript (CT) or a formal presentation (IP), the most fitting category for a timely announcement of key operational/clinical highlights is 'Earnings Release' (ER), as these releases often contain the most critical, summarized updates for investors, even if the primary focus isn't quarterly revenue/profit figures. It is not a Report Publication Announcement (RPA) because it contains the actual data summary, not just a notice that a report is available. Given the context of clinical trial data release, ER is the best fit among the provided options for a major operational update announcement. FY 2021
2021-06-22 English
FORM 6-K
Foreign Filer Report
2021-06-16 English
Innate Pharma to Host Virtual Investor Event to Highlight Progress Against Company Strategy
Regulatory Filings Classification · 95% confidence The document is a press release dated June 16, 2021, announcing that Innate Pharma will host a 'virtual investor event' on June 23, 2021, to highlight progress on its strategy, lacutamab data, and ANKET platform. This document is not the actual presentation, earnings release, or a formal regulatory filing like a 10-K or IR. It is an announcement about a future event where presentations will be given. This fits the description of an Investor Presentation (IP) announcement or, more broadly, a communication intended for investors regarding company strategy and pipeline updates, often preceding or accompanying such events. However, since the content details scientific data presentations (which are often precursors to Investor Presentations or Earnings Releases), and the core purpose is to inform investors about upcoming strategic updates, it aligns best with the Investor Presentation (IP) category, as it is detailing what will be presented to investors. It is not a short announcement of a report release (RPA/RNS), as it contains substantial background information on the drug candidates and the trial (TELLOMAK). Given the focus on strategy and pipeline updates presented to investors, IP is the most specific fit.
2021-06-16 English
Innate Pharma Présentera les Progres de sa Strategie Lors d'un Événement Virtuel a Destination des Investisseurs
Report Publication Announcement Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces that Innate Pharma will host a virtual event for investors on June 23, 2021, to present progress on its strategy, including data updates on lacutamab and the ANKETTM platform. This announcement details an upcoming event where presentations and Q&A sessions will occur, focusing on scientific and strategic updates for investors. This structure—announcing an upcoming investor presentation event—most closely aligns with the purpose of an Investor Presentation (IP), which typically involves detailed strategic and scientific updates, even if the document itself is the announcement of the event rather than the presentation slides. Since the content describes what will be presented (data, strategy, platform details), it is fundamentally related to an Investor Presentation. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a simple report publication announcement (RPA), as it is providing substantive forward-looking and scientific information about future presentations.
2021-06-16 French
FORM 6-K
Foreign Filer Report
2021-06-14 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.